Brief: Surface Oncology Presents Promising Preclinical Data For Lead Immunotherapy Product Candidates
09/04/2021 13:34
April 9 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY PRESENTS PROMISING PRECLINICAL DATA FOR
LEAD
IMMUNOTHERAPY PRODUCT CANDIDATES AT THE AMERICAN ASSOCIATION FOR
CANCER RESEARCH ANNUAL MEETING
Source text for Eikon: ID:nGNX9bmqSr
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing